Filamentous Fungus-Produced Human Monoclonal Antibody Provides SARS-CoV-2 Protection in Hamster and Non-Human Primate Models (preprint)

ABSTRACT

Monoclonal antibodies are an increasingly important tool for prophylaxis and treatment of acute virus infections like those with SARS-CoV-2. However, their use is largely limited by the length of development, yield and high production costs, as well as the need for continuous adaptation to newly emerging virus variants. Here we have used the filamentous fungus expression system Thermothelomyces heterothallica(C1), which has a natural high biosynthesis capacity for secretory enzymes and other proteins further enhanced by genetic engineering of the wild-type fungus, to produce a human monoclonal IgG1 antibody (HuMab 87G7) that neutralises SARS-CoV-2 variants of concern (VOCs) Alpha, Beta, Gamma, Delta, and Omicron. Like its mammalian cell produced equivalent, C1 produced HuMab 87G7 broadly neutralised SARS-CoV-2 VOCs in vitro and it also provided protection against Omicron and Delta VOCs in both hamsters and non-human primates, respectively. The only notable difference between the two versions was their N-linked glycosylation patterns detected by glyoproteomic analysis. Taken together, these findings demonstrate potential of the C1 expression system as a promising technology platform for the development of HuMabs in preventive and therapeutic medicine.